AstraZeneca proposes $124 per share cash takeover of Rhythm Pharma

The significance here is strategic rather than financial: a large-cap pharma moving on a rare-disease specialist signals continued appetite for bolt-on acquisitions in niche metabolic and genetic conditions, where competition for assets is already tight. A fixed all-cash structure removes financing ambiguity and puts the focus squarely on whether the target's board engages. What remains unknown is everything that usually decides such deals — regulatory review, timing, and any competing interest — so whether this proposal becomes a signed agreement or stays a public approach is the open question worth watching.